Research location
Redmond
Washington, United States
Advertisement
Research activity in Redmond
Washington, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 27 trials and 27 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Redmond
27 linked trials · page 1 of 1A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06 · 1 site observation
RECRUITING
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 · 2026-05-11 · 1 site observation
RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 · 2026-03-23 · 1 site observation
RECRUITING
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475 · 2025-03-28 · 1 site observation
RECRUITING
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · 2026-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · 2025-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895 · 2025-04-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 · 2024-11-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or OverweightNCT06643728 · 2024-10-21 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · 2024-04-10 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · 2023-09-22 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)NCT05662332 · 2023-01-14 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
HbA1c Variation StudyNCT05189938 · 2021-12-20 · 1 site observation
COMPLETED
A Study of LY3502970 in Participants With Type 2 Diabetes MellitusNCT05048719 · 2021-09-15 · 1 site observation
COMPLETED
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRCNCT03428295 · 2017-06-22 · 1 site observation
SUSPENDED
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their ChildrenNCT02129049 · 2014-04-01 · 1 site observation
COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung CancerNCT01620190 · 2012-12-02 · 1 site observation
COMPLETED
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerNCT00733408 · 2008-04-23 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.